Asahi Kasei (JP:3407) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Asahi Kasei Corporation successfully completed its tender offer for shares of Calliditas Therapeutics AB, with the acquisition resulting in Calliditas becoming a wholly-owned subsidiary. This strategic move is expected to strengthen Asahi Kasei’s presence in the U.S. and European pharmaceutical markets, particularly in the renal and autoimmune disease sectors, and presents new in-licensing opportunities as a global pharma company. The tender offer, which was well received, resulted in Asahi Kasei purchasing approximately 93.30% of Calliditas outstanding shares, costing around SEK 10.5 billion.
For further insights into JP:3407 stock, check out TipRanks’ Stock Analysis page.
